Showing results (451-460 of 467) with videos related to
Sort By:
Pageof 47
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.Prehospital Emergency Care|November 4, 2021
Impact of Prehospital Pain Management on Emergency Department Management of Injured ChildrenM I Harris, K M Adelgais, S W Linakis, et al.Frontiers in Cardiovascular Medicine|January 27, 2023
MITEA: A dataset for machine learning segmentation of the left ventricle in 3D echocardiography using subject-specific labels from cardiac magnetic resonance imagingDebbie Zhao, Edward Ferdian, Gonzalo D Maso Talou, et al.Gynecologic Oncology|February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 studyFabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 TrialPaul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 TrialPaul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 20, 2026
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trialJonathan A Ledermann, Alain Lortholary, Richard T Penson, et al.Pageof 47